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Effects of ribavirin on hepatitis C-associated nephrotic syndrome
in four liver transplant recipients.
Background. Hepatitis C virus infection (HCV) is associated
with a variety of extrahepatic disorders such as membranoprolif-
erative glomerulonephritis (MPGN), which is generally due to
cryoglobulinemia. After liver transplantation for HCV cirrhosis,
alpha-interferon treatment against the recurrence of HCV in the
liver graft is poorly effective and may induce intractable graft
rejection.
Methods. We describe the cases of four liver transplant recipi-
ents treated with ribavirin for HCV-related glomerulopathy and
nephrotic syndrome.
Results. The nephrotic syndrome was attenuated or disappeared
during ribavirin therapy, and patients showed a marked decrease
in proteinuria and an increase in albuminemia. The syndrome
relapsed in two patients when ribavirin therapy was stopped, and
a favorable response was again obtained in both cases when the
treatment was resumed. The main adverse effect of ribavirin was
anemia in two patients with renal impairment. No graft rejection
occurred.
Conclusions. These findings suggest that continuous therapy
with low doses of oral ribavirin may improve the proteinuria of
hepatitis C-related glomerulonephritis, at least in liver transplant
recipients.
Hepatitis C virus (HCV) infection can be associated with
a variety of extrahepatic immunologic disorders. The kid-
ney is one of the major targets of these disorders, the most
common complication being membranoproliferative glo-
merulonephritis, generally due to cryoglobulinemia. Pa-
tients with HCV infection and membranoproliferative glo-
merulonephritis (MPGN) generally have elevated
transaminase levels, low complement levels, proteinuria,
serum rheumatoid factor and HCV RNA. A positive
relationship with a viral load has been suggested, and
antiviral treatments such as alpha-interferon have been
used with variable results [1, 2]. Other treatments such as
plasmapheresis have been attempted, but have potentially
severe adverse effects [3, 4].
HCV cirrhosis is one of the most common indications for
liver transplantation. After liver transplantation, HCV of-
ten recurs in the liver graft and the level of viral replication
is much higher than in immunocompetent patients [5]. Due
to HCV, the underlying kidney disease and the use of
immunosuppressive drugs such as cyclosporine and FK506
can seriously complicate the management of these patients.
Furthermore, the use of alpha-interferon, the classical
treatment for HCV infection, is difficult in this setting.
Indeed, alpha-interferon is poorly efficient and, given its
immunostimulating properties, may induce intractable
graft rejection in kidney [6] and liver transplant patients [7].
Recently, ribavirin (1-b-D-Ribofuranosyl-1,2,4-triazole-3-
carboxamide; Virazole; ICN, Costa Mesa, CA, USA), a
nucleoside analog, has been used to treat HCV infection,
although it has little or no intrinsic antiviral activity. Its
activity seems to be synergistic with that of alpha-interferon
in immunocompetent subjects. Its main adverse effect is
nonimmune hemolytic anemia, and it does not induce
organ rejection.
We describe the cases of four liver transplant recipients
with glomerulonephritis due to HCV infection who re-
ceived ribavirin for the nephrotic syndrome.
METHODS
Patients
Four liver transplant patients with a nephrotic syndrome
associated with HCV infection were treated with ribavirin
in an open trial of ribavirin involving a total of 24 patients.
The other patients had normal renal function. Blood
samples were obtained for complete cell counts and routine
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biochemical tests. Rheumatoid factor and C3 were quanti-
fied by nephelometry (Behring, Marburg, Germany). Se-
rum proteins were separated by zone electrophoresis on
agarose (Sebia, Issy-les-Moulineaux, France) and immuno-
fixation electrophoresis was done with the Sebia agarose gel
IF kit. Cryoglobulins were isolated from serum stored for
seven days (4°C; 0.1 g/liter sodium azide). Cryoglobulin
isolation and characterization by immunoblotting was done
according to Musset et al [8]. Serum levels were measured
as the total protein concentration of each isolated cryopre-
cipitate by reading absorbance at 280 nm. Serum HCV
RNA was quantified with a commercial PCR assay (Am-
plicor HCV monitor; Roche Diagnostic System, Branch-
burg, PA, USA) estimating the number of HCV genome
copies/ml. Hepatitis B virus (HBV) DNA was quantified
with the Digene Hybrid Capture System (Murex Diagnostic
Inc., Norcross, GA, USA).
The grade and stage of chronic hepatitis were assessed
according to the METAVIR classification [9].
Transjugular renal biopsy was performed. Two-millime-
ter sections of biopsy tissue were examined after Bouin
fixation and paraffin embedding. When frozen tissue was
available immunofluorescence studies were performed.
Case reports
Patient 1. Patient 1, a 54-year-old woman, was trans-
planted for end-stage cirrhosis due to hepatitis B, Delta
and C viruses. There was a ten-year history of intractable
ascites, hypertension and type II diabetes. She underwent
orthotopic liver transplantation in March 1993.
Before transplantation renal function was normal and no
proteinuria was detected. Serum cryoglobulin levels were
not available but she had no clinical manifestations of
cryoglobulinemia.
After transplantation she received a standard immuno-
suppressive regimen combining azathioprine, methylpred-
nisolone and cyclosporine. Passive immunoprophylaxis with
anti-HBs immunoglobulins was given as previously de-
scribed [10], resulting in HBsAg negativity. Four months
after transplantation, serum transaminase levels increased
to three times the normal value. A liver biopsy showed mild
acute hepatitis with portal and intralobular lymphoid ag-
gregates and features of mild acute rejection. Recurrent
HCV disease was diagnosed by the presence of serum HCV
RNA. Serum HBsAg, serum HBV DNA and immunohis-
tochemical staining of HBsAg and HBcAg on the liver
biopsy specimen were negative.
One year after transplantation, in March 1994, she
developed lower limb edema and arterial hypertension. A
nephrotic syndrome with proteinuria (4.5 g/24 hr), hy-
poalbuminemia (27 g/liter) and hyperlipemia was diag-
nosed. The serum creatinine was 227 mM/liter. A renal
biopsy showed MPGN with glomerular thrombi typical of
cryoglobulin damage. Mesangial and parietal deposits of
IgM(11), IgG(1) and IgA(1) were found on immunoflu-
orescence. High levels (1.2 g/liter) of type II cryoglobulins
were detected in the serum and the rheumatoid factor was
11-fold the normal value (110 IU/ml). Characterization of
the cryoglobulins showed type II mixed IgG/IgM kappa
cryoglobulinemia. Immunofixation of serum revealed a
monoclonal peak IgG lambda component (13.1 g/liter).
Using the Monitor Amplicor quantitative reverse tran-
scribed-polymerase chain reaction (RT-PCR) test, viremia
was quantified at 248,000 copies/ml. HCV-related cryoglob-
ulin glomerulonephritis was diagnosed and antiviral ther-
apy with ribavirin (0.6 g/day then 0.8 to 1 g/day) was started
in March 1994. Table 1 summarizes renal function before
therapy, and Figure 1A shows the course of biochemical
and virologic variables. Ten months after the beginning of
antiviral treatment, in January 1995, proteinuria and edema
had disappeared and the serum creatinine was 128 mM/liter.
By this time albuminemia was in the normal range (40
g/liter) and cryoglobulinemia had fallen to 0.05 g/liter, with
a lower titer of rheumatoid factor (19.8 IU/ml); viremia was
115,000 copies/ml and alanine aminotransaminase levels
were 1.5-fold normal.
The dose of ribavirin was reduced to 0.6 g/day in May
1995 and the drug was discontinued in September 1995, 18
months after its introduction. Three months later, in De-
cember 1995, lower limb edema and arterial hypertension
recurred and renal function deteriorated (proteinuria 3.8
g/liter, albuminemia 33.4 g/liter and serum creatinine 130
mM/liter). At this time the serum cryoglobulin level was 0.27
g/liter. Aminotransferase activity was 49 IU/liter and the
serum HCV RNA titer was 342,000 copies/ml. Ribavirin
therapy was resumed in December 1995, leading, within a
month, to a new fall in viremia (47,000 copies/ml), accom-
panied by lower cryoglobulin levels (0.10 g/liter) and nor-
mal renal function (creatinine 100 mM/liter). In April 1996,
while still on antiviral treatment, proteinuria was low at 0.2
Table 1. Biological parameters of the patients before initiation of ribavirin therapy
Patient
Renal
Histology
Creatininemia
mM/liter
Albuminemia
g/liter
Proteinuria
g/24 hr
Cryoglobulins
g/liter C3
Viremia
copies/ml
1 MPGN 227 27 4.5 1.2 type II ? 248,000
2 MPGN 138 25 8.0 ,0.05 ? 750,000
3 MG 165 20 18.0 0.48 type III normal 660,000
4 MPGN 158 29 1.5 ND type II n 20,000
Abbreviations are: MPGN, Membranoproliferative glomerulonephritis; MG, Membranous glomerulonephritis.
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g/liter and aminotransferase levels were normal. At the last
visit (December 1997) the patient was well on maintenance
ribavirin antiviral treatment, with normal serum creatinine
and liver function. A renal biopsy showed unchanged
MPGN lesions.
No graft rejection occurred during ribavirin therapy and
a moderate anemia was observed.
Patient 2. Patient 2 is a 47-year-old man who underwent
orthotopic liver transplantation in October 1996 for HCV-
related cirrhosis and hepatocellular carcinoma.
Before transplantation, proteinuria (1 g/24 hr) and mild
renal failure were detected (creatinine 120 mM/liter, pro-
teinuria 1 g/24 hr). A renal biopsy showed type I membano-
proliferative glomerulonephritis. Immunofluorescence
studies showed mesangial staining for IgA (11), IgG (1),
IgM (11), C1q (1), C3 (1), kappa light chains (1) and
lambda light chains (1). Cryoglobulinemia was mildly
positive (0.1 g/liter) and was type II (IgM kappa 1 IgM
lambda 1 polyclonal IgG). Viremia, assessed using the
Amplicor HCV RNA kit, was 20,000 copies/ml.
Fig. 1. Laboratory data on patients #1 (A), #2 (B) #3 (C) and #4 (D) during ribavirin therapy. Symbols are: (p) albuminemia, g/liter; (c) proteinuria,
g/liter; (C) creatininemia, mM/liter. In (B), (C) and (D), proteinuria is expressed as g/24 hours.
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After transplantation, despite an initial immunosuppressive
regimen excluding cyclosporine and based on the use of
antilymphocyte serum, steroids and azathioprine, severe renal
failure occurred (creatinine 648 mM/liter, urea 40 mM/liter,
proteinuria 10 g/24 hr). The patient was dialyzed for one day.
Low-dose cyclosporine was introduced on day 14.
In January 1997, four months after transplantation, a
recurrence of hepatitis C was diagnosed by an increase in
aminotransferase levels (10-fold normal) associated with
high levels of serum HCV RNA (750,000 copies/ml), and
was confirmed by liver biopsy showing features of acute
lobular hepatitis. The serum creatinine was 138 mM/liter.
No cryoglobulins were detected in the serum (,0.05 g/li-
ter). Proteinuria (8 g/24 hr) and hypoalbuminemia (25
g/liter) were observed (Table 1). Mycophenolate (Mefetil;
Roche, Neuilly-sur-Seine, France) was introduced to re-
place azathioprine and maintain effective immunosuppres-
sion in spite of the low cyclosporine doses. During the same
Fig. 1. Continued. Symbol key is on page 1313.
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period, ribavirin was started (800 mg/24 hr) and two
months later the creatinine was 100 mM/liter, the urea 17
mM/liter, the proteinuria 1 g/24 hours, the albuminemia 27
g/liter and the viremia 430,000 copies/ml; the alanine
aminotransferase value was normal (Fig. 1B). At the end of
March 1997 the patient was tired and anemic (hemoglobi-
nemia 7 g/dl). No signs of hemolysis were found, and
haptoglobin levels and Coomb’s test were normal. Eryth-
roblastopenia was confirmed by bone marrow biopsy. Se-
rum parvovirus B19 DNA and antibody to B19 were
negative. Ribavirin and mycophenolate were stopped. The
nephrotic syndrome reappeared (proteinuria 8 g/24 hr,
albuminemia 27 g/liter and serum creatinine 114 mM/liter).
HCV viraemia (750,000 copies/ml) was observed in April.
In July 1997, central anemia had improved and a low dose
of ribavirin (0.4 g/24 hr) was reintroduced to treat the
deteriorating nephrotic syndrome. In August 97, the pro-
teinuria was 2 g/24 hours, albuminemia 30 g/liter, and
Fig. 1. Continued. Symbol key is on page 1313.
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creatinine was 87 mM/liter. In September 1997 he was
admitted for systemic aspergillosis and died three weeks
later from multiple organ failure.
Patient 3. Patient 3, a 47-year-old man, underwent ortho-
topic liver transplantation in January 1990 for decompen-
sated HCV-related cirrhosis. Renal function was normal
and proteinuria was negative before transplantation.
After transplantation, the immunosuppressive regimen
consisted of a standard combination of a steroid, cyclospor-
ine and azathioprine; no antiviral therapy was given. In
December 1991, two years after transplantation, a recur-
rence of hepatitis C was diagnosed by a tenfold increase in
aminotransferase levels and a liver biopsy showing chronic
hepatitis (MetavirA2F1). Alpha-interferon was tried be-
tween January and May 1992 but stopped because of signs
of chronic rejection (disappearance of biliary tracts in 8 of
12 portal tracts). Alanine aminotransferase activity was
sixfold normal. Liver histology, available first in February
1994 then yearly until December 1997, showed both stable
lesions of chronic hepatitis (Metavir A2F1) and signs of
chronic rejection (disappearance of biliary tracts in 11 of 19
portal spaces on the last biopsy). Lower limb edema and
Fig. 1. Continued. Symbol key is on page 1313.
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renal function worsened gradually, with an increase in
serum creatinine from 90 mM/liter in 1992 to 121 mM/liter in
February 1997, when a nephrotic syndrome was diagnosed.
Albuminemia was 23 g/liter and proteinuria 9 g/24 hours.
Low levels of cryoglobulins (0.26 g/liter) were found in the
serum. Characterization of the cryoglobulins showed type
III mixed cryoblobulins. Rheumatoid factor was not found.
A renal biopsy showed membranous glomerulopathy with
numerous fibrotic glomeruli, capillary wall thickening and
subepithelial spikes of glomerular basal membrane. Inter-
stitial tissue was focally fibrous with a degree of inflamma-
tion. The cyclosporine dose was reduced to limit renal
toxicity. Renal function worsened until August 1997 with
serum creatinine 165 mM/liter, albuminemia 20 g/liter,
cryoglobulins 0.48 g/liter, and proteinuria 18 g/24 hours.
Viremia was 660,000 copies/ml (Table 1).
Antiviral therapy with ribavirin (0.4 g/day) was started in
September 1997. In January 1998 the patient felt less tired
and lower limb edema was attenuated. Cryoglobulins had
disappeared and albuminemia was normal (33 g/liter); his
creatinine level was 150 mM/liter and the proteinuria 8 g/24
hours (Fig. 1C). Viremia was 354,000 copies/ml. The riba-
virin dose was kept low (0.4 g/day) because of the renal
impairment. The last available hemoglobin value was 10
g/dl. In March 1998, renal function remained stable with a
fall in proteinuria to 4.8 g/24 hours and a creatinine level of
166 mM/liter.
No graft rejection occurred during ribavirin therapy and
a moderate anemia was observed.
Patient 4. Patient 4, a 47-year-old woman, underwent
orthotopic liver transplantation in January 1986 for primary
biliary cirrhosis. Immunosuppression was based on cyclo-
sporine, steroids and azathioprine. The post-transplant
course was marked by the diagnosis of HCV infection in
1993. In April 1994, a liver biopsy showed chronic hepatitis
(Metavir A2F3) associated with positive serum HCV RNA.
Before transplantation she had normal renal function
which remained so until April 1997, when she developed
edema and proteinuria (1.5 g/24 hr). The serum creatinine
was 158 mM/liter and the albuminemia 29 g/liter, C3 and C4
were below normal values and the viremia was 20,000
copies/ml; type II mixed IgA/IgM lambda cryoglobulinemia
was found. A renal biopsy showed type I membranoprolif-
erative glomerulonephritis (Table 1).
She was treated with ribavirin (0.6 g/24 hr). During the
first four weeks of therapy the edema improved and renal
function stabilized (serum creatinine 169 mM/liter, albumin-
emia 33 g/liter and proteinuria 1.0 g/24 hr; Fig. 1D).
However, anemia occurred (6.3 g/dl) and a drastic fall in
serum haptoglobin levels (0.18 g/liter) was found in Sep-
tember 1997. Ribavirin treatment was stopped, and one
month later the anemia had partially recovered (9 g/dl).
However, serum creatinine levels were increased to 224
mM/liter and the edema and ascites worsened. In February
1998, viremia was 134,000 copies/ml, proteinuria 0.2 g/24
hours, cryoglobulins 0.17 g/liter, creatinine 306 mM/liter,
albuminemia 32 g/liter) and a liver biopsy showed chronic
hepatitis (Metavir A1F3). Renal biopsy showed glomeru-
losclerosis, explaining the low proteinuria. The patient is
currently awaiting combined kidney and liver retransplan-
tation.
DISCUSSION
We report our experience of ribavirin therapy in four
liver transplant patients with HCV glomerulopathy. Al-
though this was a nonrandomized pilot study, ribavirin
appeared to have interesting effects. Indeed, the nephrotic
syndrome improved or ceased during ribavirin therapy in
all four cases, with a marked fall in proteinuria and an
increase in albuminemia. Two patients relapsed when
ribavirin was stopped, and a further favorable response was
obtained when ribavirin was resumed in both cases.
The nephrotic syndrome is a rare but severe complica-
tion of HCV disease. Given its ability to inhibit viral
replication, alpha-interferon has also been used in the
treatment of extrahepatic complications of HBV and HCV
infection. A proportion of patients with HBV infection and
MPGN treated with alpha-interferon show an improve-
ment in the nephrotic syndrome [11–15]. As regards pa-
tients with HCV infection associated with cryoglobuline-
mia, a study showed the suppression of viral replication and
a decrease in cryoglobulinemia and serum creatinine in 15
of 25 infected patients treated with alpha-interferon [1].
Johnson et al treated 14 patients with HCV-associated
MPGN with alpha-interferon for 6 to 12 months [2].
Proteinuria fell by 65%, liver enzymes normalized and
viremia decreased, although there was no significant
change in serum creatinine. Stehman-Breen et al reported
a fall in aminotransferases and viremia in two patients
treated with alpha-interferon for HCV-related membra-
nous glomerulonephritis, whereas the nephrotic syndrome
worsened in a third patient [16].
After liver transplantation, however, alpha-interferon
treatment for recurrent HCV disease is associated with an
increased incidence of graft rejection [7], reducing the
utility of this drug in the treatment of cryoglobulinemia and
its clinical manifestations in this setting. Few cases have
been reported in the literature, and most concerned cryo-
globulin-associated MPGN. This was also the case of the
patients of our study, despite the fact that we did not find
cryoglobulins in the serum of patient #2 after transplanta-
tion, and that the renal histology of patient #3 showed
membranous glomerulonephritis.
Immunosuppressive treatment with steroids, cytotoxic
agents (cyclophosphamide or chlorambucil), and/or plas-
mapheresis have been used in situations where renal im-
pairment is severe. Unfortunately, responses are rare and
relapses frequent. Safadi et al reported the case of a patient
who developed a nephrotic syndrome after orthotopic liver
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transplantation, due to HCV-related cryoglobulins; plas-
mapheresis without antiviral therapy led to a reduction in
the cryoglobulinemia without improving symptoms [11]. In
another study Gournay et al reported that plasmapheresis
and the addition of cyclophosphamide led to an improve-
ment in the renal disease in one of two cases of MPGN [4].
However, plasmapheresis performed in a patient who
developed a nephrotic syndrome following the recurrence
of HCV led to a marked reduction in cryoglobulin levels
but no improvement in the nephrotic syndrome [3].
Recently, ribavirin has been used to treat chronic HCV
infection, and previous studies have shown that oral riba-
virin is well tolerated and induces a significant decrease in
serum aminotransferases but not in HCV RNA levels
[17–19]. However, no information is available on the effect
of ribavirin in HCV-related glomerulopathy. In our study
the recurrence of HCV infection in three patients and its
occurrence in one patient after orthotopic liver transplan-
tation was diagnosed by high levels of HCV RNA in blood
and features of hepatitis on liver biopsy, in the absence of
HBV recurrence. All the patients had an improvement or
cessation of the nephrotic syndrome during ribavirin ther-
apy, with a marked decrease in proteinuria and an increase
in albuminemia. Two patients relapsed when ribavirin
therapy was stopped, and a favorable response was again
obtained when the treatment was resumed in both cases.
The most striking finding was that viremia was not signifi-
cantly changed, despite the apparent effect on both the
nephrotic syndrome and aminotransferase activity. We also
observed this discrepancy between the biological and viro-
logic responses in the other 20 patients of the open trial
including 24 liver transplant patients treated with ribavirin.
Taken together, our findings suggest that ribavirin acts
on HCV-related glomerular or liver lesions through a
mechanism other than a reduction in viral replication. One
possibility is an immunomodulating effect [20, 21]. One of
the authors recently showed that a decrease in intrahepatic
HCV replication occurs after liver transplantation together
with the progression to chronic hepatitis [21]. This suggests
that liver injury may be due to immunological phenomena,
even after liver transplantation. It is noteworthy that the
immunosuppressive regimen was relatively mild in all four
patients reported here, either because they were trans-
planted some time previously, or because of renal failure. It
is tempting to speculate that the nonspecific effects of this
drug might prove beneficial in nonviral immune glomeru-
lonephritis.
None of the four patients had clinical graft rejection after
ribavirin was started. The drug was well tolerated in two
patients, whereas anemia occurred in the other two cases.
In these latter patients the dose may have been too high, as
the half-life of ribavirin elimination is very long and renal
impairment considerably favors adverse effects, including
anemia. However, the mild global toxicity of ribavirin, as
reported in the treatment of chronic hepatitis C [17–19, 22],
is compatible with continuous therapy until an alternative
emerges. Moreover, long-term use may be limited also by
our lack of knowledge on emergence of resistance and/or
direct renal effects.
Our findings strongly suggest that ribavirin is effective in
treating the clinical and biological manifestations of the
nephrotic syndrome due to HCV-related glomerulonephri-
tis, with or without cryoglobulinemia, after liver transplan-
tation. As for the reduction in aminotransferase activity,
this was not linked to the ability of ribavirin to reduce
viremia, therefore pointing to an immunomodulatory
mechanism. As ribavirin does not seem to increase the
incidence of rejection (contrary to alpha-interferon), it
could be the antiviral drug of choice in this setting.
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